ArticleFrontiers in pharmacology2026
Evaluation of the therapeutic efficacy of the dextromethorphan-bupropion combination and its mediating pathways in a mouse model of major depressive disorder.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major depressive disorder (MDD) is associated with multiple pathophysiological mechanisms, including dysregulation of monoaminergic systems, excessive glutamatergic activity, reduced neurotrophic support, inflammation, and oxidative stress. The combination of dextromethorphan, an N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, with bupropion, a dopamine/norepinephrine reuptake inhibitor, has been reported to exert rapid antidepressant effects. In the present study, we evaluated the therapeutic effects of the dextromethorphan-bupropion combination on behavioral outcomes and neurotransmitter, inflammatory, and apoptotic pathways in a mouse model of MDD. Methods: A total of 36 BALB/c mice were randomly assigned to four groups: Control, CUMS, DXM + BUP, and CUMS + DXM + BUP. The chronic unpredictable mild stress (CUMS) protocol was applied for 6 weeks. Depressive-like behaviors were assessed using the sucrose preference test, open field test, and forced swim test. At the end of the experiment, hippocampal and prefrontal cortex tissues were collected. Serum serotonin, dopamine, GABA, glutamate, and norepinephrine levels were quantified by ELISA. Gene expression levels of Results: The CUMS group exhibited significant weight loss, anhedonia, increased immobility, elevated glutamate and norepinephrine levels, and reduced serotonin and dopamine levels. In addition, decreased expression of neurotrophic genes and increased expression of Conclusion: The dextromethorphan-bupropion combination ameliorated CUMS-induced depressive phenotypes at behavioral, neurotrophic, inflammatory, and apoptotic levels. These findings suggest that this combination represents a potent multimodal therapeutic candidate for stress-related depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.